Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

Merck reports 2024 sales at $64.2 billion

The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion

Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024